TAK
Takeda Pharmaceutical Company Limited
TAK lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
TAK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
TAK's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
TAK PE Valuation
TAK has no meaningful PE right now: it lost money over the past year.
TAK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TAK's earnings to grow and its profitability to improve, with its revenue holding steady.
TAK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.35 | +30% |
| Q2 2025 | $0.27 | -6.9% |
| Q1 2025 | $0.21 | -28% |
| Q4 2024 | $0.41 | +17% |
| Q3 2024 | $0.57 | +50% |
| Q2 2024 | $0.29 | -52% |
| Q1 2024 | $0.29 | -54% |
| Q4 2023 | $0.35 | -36% |
TAK earned $0.75 per share over the past year, up 83% from the year before.
TAK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.4B | +6.7% |
| Q2 2026 | $7.6B | +10% |
| Q1 2026 | $7B | +5.8% |
| Q4 2025 | $7.6B | +6% |
| Q3 2025 | $7B | -5.4% |
| Q2 2025 | $6.9B | -8.4% |
| Q1 2025 | $6.6B | +0.2% |
| Q4 2024 | $7.2B | +3% |
TAK's revenue has grown year over year for four quarters in a row: $7.4B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +11 points |
| Q2 2026 | 17% | N/A |
| Q1 2026 | 4.3% | -12 points |
| Q4 2025 | 16% | +23 points |
| Q3 2025 | 6.2% | +0.4 points |
| Q2 2025 | 17% | +2.9 points |
| Q1 2025 | -7.1% | -6.2 points |
| Q4 2024 | 5.8% | -3.6 points |
TAK's operating margin was 17% last quarter, up 11 points from the same quarter a year ago.
TAK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $462.7M | -47% |
| Q1 2026 | $63.5M | -92% |
| Q4 2025 | $945.7M | -54% |
| Q3 2025 | $2B | +73% |
| Q2 2025 | $879.7M | +735% |
| Q2 2025 | $879.7M | +735% |
| Q1 2025 | $811.3M | -40% |
| Q4 2024 | $2.1B | +372% |
TAK still generates free cash flow, though less than at its 2022 peak: $3.5B over the past year.
TAK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +1.7% | +54.5M shares |
| 3 years | +2.5% | +78.8M shares |
| 5 years | +1.5% | +48.6M shares |
| Available history | +3% | +94M shares |
TAK has 3.2B diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $6.3M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $323.4M |
| Q1 2025 | $313.3M |
| Q4 2024 | — |
| Q3 2024 | — |
TAK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 3.6x | Elevated |
| Q4 2024 | 3.6x | Elevated |
| Q3 2024 | 3.3x | Elevated |
| Q2 2024 | 4.2x | High |
| Q1 2024 | 4.0x | High |
TAK's net debt is about 3.1 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
TAK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.9 | Overbought |
| Stochastic | 89.0 | Overbought |
TAK's weekly RSI is 74 (overbought) and its Stochastic is 89 (overbought).
TAK PE vs Healthcare Sector
| Metric | TAK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TAK has no meaningful PE right now: it lost money over the past year.
TAK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.8 | 6.7% above |
| 20 week MA | $18.5 | 14% above |
| 50 week MA | $17.4 | 21% above |
| 100 week MA | $15.9 | 33% above |
| 200 week MA | $15.3 | 38% above |
TAK is in an uptrend: it's above all five of its weekly moving averages, and 38% above its 200-week average.
TAK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.8 | $18.1 | -8.7% |
| 2021 | $18.1 | $13.8 | -24% |
| 2022 | $13.8 | $15.5 | +13% |
| 2023 | $15.5 | $14.3 | -8.2% |
| 2024 | $14.3 | $13.3 | -7% |
| 2025 | $13.3 | $15.7 | +18% |
| 2026 YTD | $15.7 | $21.1 | +35% |
TAK is up 35% so far in 2026, after finishing lower in four of the previous six years.